Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Malignant transformation: the role of MRS.

Jiang L, Wijnen JP, Glunde K.

Eur J Radiol. 2012 Sep;81 Suppl 1:S66-8. doi: 10.1016/S0720-048X(12)70026-8. No abstract available.

PMID:
23083608
2.

L-COSY of breast cancer at 3T.

Ramadan S, Baltzer PA, Lin A, Stanwell P, Box H, Kaiser WA, Mountford CE.

Eur J Radiol. 2012 Sep;81 Suppl 1:S129-31. doi: 10.1016/S0720-048X(12)70053-0. No abstract available.

PMID:
23083559
3.

In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy.

Russo F, Mazzetti S, Grignani G, De Rosa G, Aglietta M, Anselmetti GC, Stasi M, Regge D.

Eur Radiol. 2012 May;22(5):1131-9. doi: 10.1007/s00330-011-2350-9. Epub 2011 Dec 4.

PMID:
22138734
4.

MR-spectroscopy at 1.5 tesla and 3 tesla. Useful? A systematic review and meta-analysis.

Baltzer PA, Dietzel M, Kaiser WA.

Eur J Radiol. 2012 Sep;81 Suppl 1:S6-9. doi: 10.1016/S0720-048X(12)70003-7. Review. No abstract available.

PMID:
23083604
5.

What is new in breast MRI spectroscopy.

Nelson MT, Bolan PJ, Garwood M, Everson L, Emory T, Kuehn-Hajder J.

Eur J Radiol. 2012 Sep;81 Suppl 1:S107-8. doi: 10.1016/S0720-048X(12)70043-8. No abstract available.

PMID:
23083548
6.

Quantitative multivoxel proton chemical shift imaging of the breast.

Sijens PE, Dorrius MD, Kappert P, Baron P, Pijnappel RM, Oudkerk M.

Magn Reson Imaging. 2010 Apr;28(3):314-9. doi: 10.1016/j.mri.2009.11.004. Epub 2010 Jan 13.

PMID:
20071119
7.

CEST-imaging: A new contrast in MR-mammography by means of chemical exchange saturation transfer.

Schmitt B, Trattnig S, Schlemmer HP.

Eur J Radiol. 2012 Sep;81 Suppl 1:S144-6. doi: 10.1016/S0720-048X(12)70060-8. No abstract available.

PMID:
23083567
8.

Magnetic resonance spectroscopy of the breast: current status.

Bolan PJ.

Magn Reson Imaging Clin N Am. 2013 Aug;21(3):625-39. doi: 10.1016/j.mric.2013.04.008. Epub 2013 May 23. Review.

PMID:
23928249
9.

A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer.

Villeirs GM, Oosterlinck W, Vanherreweghe E, De Meerleer GO.

Eur J Radiol. 2010 Feb;73(2):352-6. doi: 10.1016/j.ejrad.2008.10.034. Epub 2008 Dec 11.

PMID:
19084363
10.

Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy.

Zeng Q, Liu H, Zhang K, Li C, Zhou G.

Magn Reson Imaging. 2011 Jan;29(1):25-31. doi: 10.1016/j.mri.2010.07.017. Epub 2010 Sep 15.

PMID:
20832225
11.

MR spectroscopy of head and neck cancer.

Abdel Razek AA, Poptani H.

Eur J Radiol. 2013 Jun;82(6):982-9. doi: 10.1016/j.ejrad.2013.01.025. Epub 2013 Feb 26. Review.

PMID:
23485098
12.

Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification.

Lee CW, Lee JH, Kim DH, Min HS, Park BK, Cho HS, Kang HG, Suh JS, Ehara S.

Clin Imaging. 2010 Jan-Feb;34(1):47-52. doi: 10.1016/j.clinimag.2009.03.013.

PMID:
20122519
13.

MR spectroscopy in the breast clinic is improving.

Mountford CE, Schuster C, Baltzer PA, Malycha P, Kaiser WA.

Eur J Radiol. 2012 Sep;81 Suppl 1:S104-6. doi: 10.1016/S0720-048X(12)70042-6. No abstract available.

PMID:
23083547
14.

Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines.

Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL.

Radiology. 2007 Nov;245(2):499-506. Epub 2007 Sep 21.

PMID:
17890357
15.

In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla.

Booth SJ, Pickles MD, Turnbull LW.

BJOG. 2009 Jan;116(2):300-3. doi: 10.1111/j.1471-0528.2008.02007.x.

16.

Monitoring of treatment response after chemoradiotherapy for head and neck cancer using in vivo 1H MR spectroscopy.

King AD, Yeung DK, Yu KH, Mo FK, Hu CW, Bhatia KS, Tse GM, Vlantis AC, Wong JK, Ahuja AT.

Eur Radiol. 2010 Jan;20(1):165-72. doi: 10.1007/s00330-009-1531-2. Epub 2009 Aug 5.

PMID:
19652977
17.

Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings.

Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, Moskowitz CS, Ishill NM, Reuter VE, Touijer K, Zakian KL, Koutcher JA.

Radiology. 2008 Feb;246(2):480-8. doi: 10.1148/radiol.2462070368.

PMID:
18227542
18.

Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.

Canese R, Pisanu ME, Mezzanzanica D, Ricci A, Paris L, Bagnoli M, Valeri B, Spada M, Venditti M, Cesolini A, Rodomonte A, Giannini M, Canevari S, Podo F, Iorio E.

NMR Biomed. 2012 Apr;25(4):632-42. doi: 10.1002/nbm.1779. Epub 2011 Oct 24.

PMID:
22020805
19.

Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.

Hsieh TJ, Li CW, Chuang HY, Liu GC, Wang CK.

J Comput Assist Tomogr. 2008 Nov-Dec;32(6):987-94. doi: 10.1097/RCT.0b013e31815b9ce9.

PMID:
19204465
20.

The infrared spectral signatures of disease: extracting the distinguishing spectral features between normal and diseased states.

Diem M, Papamarkakis K, Schubert J, Bird B, Romeo MJ, Miljković M.

Appl Spectrosc. 2009 Nov;63(11):307A-318A. doi: 10.1366/000370209789806894. No abstract available.

PMID:
19891826

Supplemental Content

Support Center